CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Clinical trials for CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immunotherapy combo shows promise for Hard-to-Treat stomach cancer
Disease control OngoingThis study tests whether adding chemotherapy to an immunotherapy drug (atezolizumab) works better than immunotherapy alone for patients with a specific genetic type of stomach or gastroesophageal junction cancer (MSI-H/dMMR). About 240 adults with cancer that hasn't spread far wi…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 09:38 UTC
-
New combo before surgery shows promise against esophageal cancer
Disease control OngoingThis study tests whether adding immunotherapy drugs (atezolizumab and tiragolumab) to standard chemotherapy before surgery can better control esophageal or gastroesophageal cancer. About 43 adults with stage II or III cancer will receive the drug combination, then undergo surgery…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 17, 2026 09:36 UTC
-
Heated chemo during surgery may stop stomach Cancer's return
Disease control ENROLLING_BY_INVITATIONThis study tests whether giving heated chemotherapy directly into the abdomen during surgery can prevent stomach cancer from returning in the belly lining. It includes 16 adults with stomach or gastroesophageal junction cancer at high risk of recurrence. The approach aims to kill…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated May 17, 2026 09:32 UTC
-
New combo therapy shows promise in shrinking esophageal tumors before surgery
Disease control OngoingThis study tests a treatment plan for people with esophageal cancer that hasn't spread. Before surgery, patients receive chemotherapy, radiation, and two immunotherapy drugs (pembrolizumab and lenvatinib) to shrink tumors and boost the immune system's attack on cancer. The goal i…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Immunotherapy combo shows promise in esophageal cancer fight
Disease control TerminatedThis study looks at whether adding two immunotherapy drugs, nivolumab and ipilimumab, to standard chemotherapy and radiation can help shrink tumors in people with esophageal or gastroesophageal junction cancer before surgery. About 278 adults with stage II to IVA cancer will be e…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 14, 2026 12:02 UTC
-
Cancer-Killing virus joins Chemo-Radiation in fight against esophageal cancer
Disease control OngoingThis early-phase trial tests whether adding a cancer-killing virus (OBP-301) to standard chemotherapy and radiation is safe for people with advanced esophageal or gastroesophageal cancer who cannot have surgery. The virus is designed to infect and destroy tumor cells. The study e…
Matched conditions: CLINICAL STAGE II GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Disease control
Last updated May 13, 2026 16:02 UTC